From pathogenesis to therapy--Perspective on treatment strategies in fibrotic diseases.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmacological Research

• Publication date

  2015-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.phrs.2015.06.012PMID 26188266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis

  2015cited by this paper
• Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies

  2015cited by this paper
• Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis

  2015cited by this paper
• Transforming growth factor β—at the centre of systemic sclerosis

  2014cited by this paper
• Nintedanib: First Global Approval

  2014cited by this paper
• IL-6 biology: implications for clinical targeting in rheumatic disease

  2014cited by this paper
• Therapeutic modulation of Notch signalling — are we there yet?

  2014cited by this paper
• Combination therapy: the future of management for idiopathic pulmonary fibrosis?

  2014cited by this paper
• Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.

  2014cited by this paper
• Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages

  2014cited by this paper
• IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice

  2014cited by this paper
• Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

  2014cited by this paper
• Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis

  2013cited by this paper
• Activation of pregnane X receptor inhibits experimental dermal fibrosis

  2013cited by this paper
• Interleukin-33 potentiates bleomycin-induced lung injury.

  2013cited by this paper
• The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis

  2013cited by this paper
• Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis.

  2013cited by this paper
• Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement.

  2013cited by this paper
• Differential role of regulatory T cells in early and late stages of pulmonary fibrosis.

  2013cited by this paper
• Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis

  2013cited by this paper
• IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis

  2013cited by this paper
• Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs

  2013cited by this paper
• Riociguat for the treatment of pulmonary arterial hypertension.

  2013cited by this paper
• Sustained β-catenin activity in dermal fibroblasts is sufficient for skin fibrosis

  2012cited by this paper
• Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.

  2012cited by this paper
• Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells.

  2012cited by this paper
• Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease.

  2012cited by this paper
• Drugging Wnt signalling in cancer

  2012cited by this paper
• β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis

  2012cited by this paper
• Mechanisms of fibrosis: therapeutic translation for fibrotic disease

  2012cited by this paper
• Innovative antifibrotic therapies in systemic sclerosis

  2012cited by this paper
• T cells in systemic sclerosis: a reappraisal.

  2012cited by this paper
• Wnt signaling.

  2012cited by this paper
• Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling

  2012cited by this paper
• Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

  2012cited by this paper
• Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis.

  2012cited by this paper
• Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

  2012cited by this paper
• Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis

  2012cited by this paper
• CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis

  2012cited by this paper
• Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway

  2011cited by this paper
• Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?

  2011cited by this paper
• Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease

  2011cited by this paper
• Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis

  2011cited by this paper
• Axin Pathway Activity Regulates in Vivo pY654-β-catenin Accumulation and Pulmonary Fibrosis*

  2011cited by this paper
• Platelet-derived serotonin links vascular disease and tissue fibrosis

  2011cited by this paper
• Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis

  2011cited by this paper
• Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis.

  2011cited by this paper
• Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis

  2011cited by this paper
• Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation.

  2011cited by this paper
• Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

  2011cited by this paper
• Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis

  2011cited by this paper
• Mechanisms and functions of Hedgehog signalling across the metazoa

  2011cited by this paper
• Effect of Bosentan on Systemic Sclerosis-associated Interstitial Lung Disease Ineligible for Cyclophosphamide Therapy: A Prospective Open-label Study

  2011cited by this paper
• Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.

  2010cited by this paper
• Animal models of systemic sclerosis: prospects and limitations.

  2010cited by this paper
• Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model.

  2010cited by this paper
• MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.

  2010cited by this paper
• Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis.

  2010cited by this paper
• Cellular and molecular aspects of vascular dysfunction in systemic sclerosis

  2010cited by this paper
• Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans.

  2010cited by this paper
• Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

  2010cited by this paper
• Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent

  2010cited by this paper
• Scleroderma.

  2009cited by this paper
• Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma

  2009cited by this paper
• Notch signaling: the core pathway and its posttranslational regulation.

  2009cited by this paper
• Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis

  2009cited by this paper
• WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis.

  2009cited by this paper
• Wnt/beta-catenin signaling promotes renal interstitial fibrosis.

  2009cited by this paper
• Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis.

  2008cited by this paper
• The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak

  2008cited by this paper
• Secreted Frizzled Related Protein 2 is a procollagen C proteinase enhancer with a role in myocardial infarction-associated fibrosis

  2008cited by this paper
• BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

  2008cited by this paper
• Cellular and molecular mechanisms of fibrosis

  2008cited by this paper
• PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.

  2008cited by this paper
• PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis

  2008cited by this paper
• PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing

  2008cited by this paper
• Systemic sclerosis: a prototypic multisystem fibrotic disorder.

  2007cited by this paper
• Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

  2007cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cited by this paper
• B cell infiltration in systemic sclerosis-associated interstitial lung disease.

  2007cited by this paper
• Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

  2006cited by this paper
• Overview of pathogenesis of systemic sclerosis.

  2006cited by this paper
• Review: recent clinical trials in epigenetic therapy.

  2006cited by this paper
• Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis

  2006cited by this paper
• Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis.

  2005cited by this paper
• Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

  2005cited by this paper
• Augmented production of transforming growth factor-β by cultured peripheral blood mononuclear cells from patients with systemic sclerosis

  2004cited by this paper
• Therapeutic Attenuation of Pulmonary Fibrosis Via Targeting of IL-4- and IL-13-Responsive Cells 1

  2003cited by this paper
• Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor*

  2003cited by this paper
• Systemic and cell type-specific gene expression patterns in scleroderma skin

  2003cited by this paper
• Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.

  2001cited by this paper
• The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.

  1999cited by this paper
• Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis.

  1999cited by this paper
• An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response.

  1999cited by this paper
• Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats.

  1998cited by this paper
• Role of thrombin in pulmonary fibrosis.

  1995cited by this paper
• Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study

  1994cited by this paper
• In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease.

  1993cited by this paper

• Emerging Trends in Phytochemical Nanomedicines for Lung Inflammation and Fibrosis Management.

  2026cites this paper
• Network-based drug repositioning of linagliptin as a potential agent for uterine fibroids targeting transforming growth factor-beta mediated fibrosis.

  2024cites this paper
• The occurrence and development mechanisms of esophageal stricture: state of the art review

  2024cites this paper
• Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms.

  2021cites this paper
• The regulatory role of the BDNF/TrkB pathway in organ and tissue fibrosis.

  2021cites this paper
• PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis

  2020cites this paper
• Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis

  2020cites this paper
• Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis

  2020cites this paper
• Tannic acid prevents macrophage-induced pro-fibrotic response in lung epithelial cells via suppressing TLR4-mediated macrophage polarization

  2019cites this paper
• SPI1/PU.1 controls fibroblast polarization and tissue fibrosis

  2019cites this paper
• Acyltransferase skinny hedgehog regulates TGFβ-dependent fibroblast activation in SSc

  2019cites this paper
• Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis

  2017cites this paper
• Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis

  2017cites this paper
• JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment

  2017cites this paper
• The control of tissue fibrosis by the inflammatory molecule LIGHT (TNF Superfamily member 14).

  2016cites this paper
• Canonical Wnt signaling in systemic sclerosis

  2016cites this paper
• Tocilizumab for systemic sclerosis: implications for future trials.

  2016cites this paper
• Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis

  2016cites this paper